➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Colorcon
Moodys
Baxter
Mallinckrodt

Last Updated: May 17, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GAMMAGARD LIQUID

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for GAMMAGARD LIQUID

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01736579 Long-Term Study of IGIV, 10% in Alzheimer´s Disease Terminated Baxalta US Inc. Phase 3 2012-11-01 The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor.
NCT02123615 ASIS for GAMMAGARD in Primary Immunodeficiency Not yet recruiting ASIS Corporation Phase 1/Phase 2 2016-01-01 ASIS Corporation (ASIS) has developed the only automatic injection system for delivery of injectable products to it's optimum/right spot, just outside of the fascia, which exists subdermally (between the skin and muscle). Bloodless basically implies longer lasting medicinal effects, and minimal side effects - advantages that reflect the NIH mission of enhancing health, lengthening life, and reducing the burdens of illness and disability. ASIS device is stabilized on the surface of the skin with negative pressure and emits an electrical current to create a bloodless cavity subdermally. ASIS device correctly, automatically, and consistently delivers therapeutic agents, yet requiring little skill of a practitioner - providing the steady and safe infusion into subdermal bloodless space of virtually any injectable product in addition to Botox, including GAMMAGARD LIQUID, Enbrel, Insulin, and Fillers, etc. According to the FDA, "This innovation will have major impact on the healthcare industry."
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for GAMMAGARD LIQUID

Condition Name

Condition Name for GAMMAGARD LIQUID
Intervention Trials
Primary Immunodeficiency 1
Alzheimer´s Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for GAMMAGARD LIQUID
Intervention Trials
Immunologic Deficiency Syndromes 1
Alzheimer Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for GAMMAGARD LIQUID

Trials by Country

Trials by Country for GAMMAGARD LIQUID
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for GAMMAGARD LIQUID
Location Trials
California 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for GAMMAGARD LIQUID

Clinical Trial Phase

Clinical Trial Phase for GAMMAGARD LIQUID
Clinical Trial Phase Trials
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for GAMMAGARD LIQUID
Clinical Trial Phase Trials
Not yet recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GAMMAGARD LIQUID

Sponsor Name

Sponsor Name for GAMMAGARD LIQUID
Sponsor Trials
ASIS Corporation 1
Baxalta US Inc. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for GAMMAGARD LIQUID
Sponsor Trials
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Harvard Business School
McKinsey
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.